Posted by Michael Wonder on 06 Mar 2022
Paediatric rare disease drug Koselugo fails to get insurance benefits
4 March 2022 - AstraZeneca’s Koselugo (selumetinib), the first rare disease treatment approved in Korea through an accelerated review due to the urgency to introduce the drug, failed to get health insurance benefits.
The Health Insurance Review and Assessment Service held a Drug Reimbursement Evaluation Committee meeting on Thursday and concluded that Koselugo was invalid for reimbursement.
